Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS
Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...
MarketBeat
More News
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday
Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...
MarketBeat
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research
Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...
MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics.
Stocktwits
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...
MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...
MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...
MarketBeat
<
1
2
>

Advertisement|Remove ads.